List of Excipients in Branded Drug TULANA

Generic Drugs Containing TULANA

Company	Ingredient	NDC	Excipient
Afaxys Pharma LLC	norethindrone	50102-200	D&C YELLOW NO. 10
Afaxys Pharma LLC	norethindrone	50102-200	FD&C YELLOW NO. 6
Afaxys Pharma LLC	norethindrone	50102-200	LACTOSE MONOHYDRATE
Afaxys Pharma LLC	norethindrone	50102-200	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TULANA?

# Of NDCs	Excipient
2	D&C YELLOW NO. 10
2	FD&C YELLOW NO. 6
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE

Tulana Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Tulana is a 0.35 mg norethindrone progestin-only oral contraceptive. Its commercial opportunity is driven less by active-ingredient exclusivity and more by formulation differentiation, access, adherence, supply reliability, and potential nonprescription positioning. The product has no biologic biosimilar exposure. Generic competition is structurally strong because norethindrone is an established small molecule with multiple marketed products and a relatively simple immediate-release tablet formulation.[1][2]

What is Tulana and how is it positioned?

Tulana contains norethindrone, a synthetic progestin used for contraception. Each tablet contains 0.35 mg of norethindrone and is taken daily without a hormone-free interval. Progestin-only pills are used by patients who cannot or prefer not to use estrogen-containing contraceptives.[1]

Attribute	Tulana
Active ingredient	Norethindrone
Strength	0.35 mg
Dosage form	Immediate-release oral tablet
Therapeutic class	Progestin-only contraceptive
Primary use	Prevention of pregnancy
FDA pathway	Prescription drug approval
Biosimilar risk	Not applicable
Core competitive set	Generic norethindrone 0.35 mg tablets, Opill, other progestin-only pills
Main formulation issue	Low-dose content uniformity, dissolution, stability and daily adherence

Tulana competes in a market that now includes Opill, the first U.S. nonprescription daily oral contraceptive. FDA approved Opill for over-the-counter use in 2023, increasing pressure on prescription-only progestin products to differentiate through access, pharmacy services, packaging, telehealth integration or formulation attributes.[3]

What excipients are used in Tulana?

Public product labeling identifies Tulana as a conventional immediate-release tablet. The inactive-ingredient profile is consistent with a low-dose compressed tablet and generally includes diluents, binders, disintegrants, glidants and lubricants. DailyMed and the approved labeling should control any final assessment of the current commercial formulation because excipient composition can change through approved manufacturing supplements.[1]

Typical functional roles are as follows:

Excipient function	Commercial purpose in a norethindrone tablet
Diluent	Provides tablet mass when the active dose is only 0.35 mg
Binder	Supports granule or tablet mechanical strength
Disintegrant	Promotes tablet breakup and drug release
Glidant	Improves powder flow and content uniformity
Lubricant	Reduces sticking and tooling friction
Moisture-control component	Protects low-dose active from degradation or variable assay
Packaging barrier	Limits moisture and oxygen exposure during shelf life

The very low active load makes blend uniformity more important than total drug mass. A formulation that uses direct compression must demonstrate reliable distribution of norethindrone throughout the powder blend. Wet granulation can improve uniformity and flow but may introduce moisture, process complexity and additional stability requirements.

Which excipient strategies could improve Tulana?

1. Lactose-free positioning

A lactose-free version could address patients with lactose intolerance, excipient avoidance preferences or restrictions associated with certain dietary practices. The commercial value is probably limited for the general contraceptive market because the tablet contains a very small total excipient burden and lactose intolerance does not automatically preclude use of pharmaceutical lactose.

The opportunity becomes more credible if the manufacturer can combine lactose-free composition with a clean-label claim, improved global market acceptability or a broader patient-access program. Substitution with microcrystalline cellulose, mannitol, dibasic calcium phosphate or another established diluent would require evaluation of blend uniformity, hardness, friability, dissolution and stability.

2. Improved swallowability

Small, smooth tablets can improve daily use. Tulana already uses a low-strength oral tablet, so the commercial gain from reducing tablet size may be modest. A formulation platform using higher-density excipients could reduce tablet volume, while a film coat could improve mouthfeel and swallowing.

Film coating also creates costs. It can increase tablet weight, manufacturing steps and packaging requirements. Coating materials must not delay dissolution or create dose variability. A coated product would be commercially useful if it supports a clear patient benefit, such as reduced sticking, improved taste or better handling.

3. Taste-masked or orally disintegrating formats

An orally disintegrating tablet, mini-tablet or sublingual product could target patients with difficulty swallowing conventional tablets. The clinical need exists, but the product would require a new formulation and likely a new regulatory strategy. Taste masking is a meaningful technical barrier because norethindrone exposure to the oral cavity may produce an unacceptable taste.

The strongest opportunity would be a product that improves access for adolescents, patients with dysphagia or users without reliable access to water. The commercial case is weaker if the product only provides convenience without reducing dosing errors or expanding the addressable population.

4. Excipient systems that improve manufacturing robustness

Because norethindrone is present at a low dose, excipient selection can reduce batch failure risk. A co-processed excipient system may improve:

• powder flow;
• segregation resistance;
• content uniformity;
• tablet tensile strength;
• dissolution reproducibility; and
• scale-up performance.

These benefits can support a stronger commercial manufacturing position even if they are invisible to patients. The most defensible intellectual property would protect a narrow composition linked to a measurable technical effect, such as improved content uniformity or dissolution under defined conditions.

5. Moisture and oxygen protection

A stable tablet can be packaged in high-barrier bottles, blister packs or unit-dose systems. Blister packaging may offer adherence benefits because users can track daily doses. It can also reduce exposure to humidity and handling contamination.

Unit-dose packaging increases packaging cost and material consumption. The economics improve if it reduces missed doses, supports mail-order dispensing or enables direct-to-consumer distribution. For a contraceptive taken every day, calendarized blister packaging is commercially more relevant than a basic bottle upgrade.

What formulation patents could protect Tulana?

Norethindrone is an old active ingredient, so broad composition-of-matter protection is not a realistic strategy. Commercially relevant patent opportunities would be narrower.

Potential patent category	Potential strength
Broad norethindrone composition patent	Very weak or unavailable
Specific excipient ratio	Moderate only if linked to a reproducible technical result
Low-dose content-uniformity process	Moderate
Orally disintegrating or taste-masked formulation	Moderate to strong if technically differentiated
Moisture-protective packaging	Moderate, often vulnerable to design-around
Calendar blister or adherence packaging	Moderate, but potentially easy to work around
New method of contraception using known norethindrone dose	Generally limited
Manufacturing process with defined controls	Moderate if process-specific and difficult to replicate

A formulation patent should avoid claiming routine excipient substitutions. Claims based only on replacing lactose with microcrystalline cellulose or adding a conventional disintegrant are vulnerable to obviousness challenges. Stronger claims would connect composition and process parameters to a demonstrated result, such as consistent assay across commercial-scale batches or rapid dissolution after accelerated storage.

When does Tulana lose exclusivity?

Tulana’s core active ingredient is not protected by modern small-molecule exclusivity economics. The relevant barriers are product-specific regulatory exclusivity, any listed patents, manufacturing know-how and commercial distribution rather than a broad norethindrone patent.

Exclusivity issue	Assessment
Active-ingredient patent	No meaningful new-molecule barrier
Biosimilar pathway	Not applicable
Generic substitution	High structural risk
Orange Book patent exposure	Must be confirmed against the current FDA listing
Formulation patent exposure	Potentially relevant only if a specific protected product exists
Regulatory exclusivity	Product-specific and dependent on the approval record
Commercial exclusivity	Dependent on supply, branding, access and channel execution

Tulana should be evaluated through the FDA Orange Book for listed patents, expiration dates, patent-use codes and any exclusivity codes. A precise patent-expiration date should not be inferred from the brand name alone because product-specific listings and approval records control the analysis.[2]

What is the Orange Book status of Tulana?

The Orange Book is the authoritative source for determining whether a drug product has listed patents and whether an ANDA applicant could file a Paragraph IV certification.[2] A Paragraph IV challenge would allege that a listed patent is invalid, unenforceable or not infringed.

For a low-dose norethindrone tablet, the most likely competitive path is an ANDA directed to pharmaceutical equivalence and bioequivalence. The commercial importance of a Paragraph IV filing depends on whether Tulana has listed formulation or method-of-use patents. If no relevant patents are listed, generic entry can proceed without a Paragraph IV dispute, subject to FDA approval and other regulatory requirements.

What patent litigation affects Tulana?

No major public patent-litigation profile can be established from the product name alone. The relevant searches should cover the NDA holder, current marketer, formulation patent owners and any ANDA applicants. Litigation risk would be concentrated in:

• formulation patents;
• packaging patents;
• method-of-use patents;
• regulatory exclusivity disputes; and
• contractual disputes involving manufacturing or distribution.

For this product class, litigation risk is likely lower than for branded extended-release products, complex injectables or biologics.

Which companies are challenging Tulana?

Generic norethindrone products already create direct competitive pressure. Opill creates a separate channel threat because it is an FDA-approved nonprescription norethindrone product.[3] The competitive landscape includes:

1. Generic prescription norethindrone manufacturers.
2. OTC Opill and its manufacturer.
3. Other progestin-only contraceptives, including drospirenone products.
4. Combined oral contraceptive manufacturers.
5. Telehealth and digital-pharmacy distributors.

The most important challenge may not be a named Paragraph IV filer. It may be substitution by low-cost generic norethindrone or migration to OTC contraception.

How does Tulana compare with Opill?

Factor	Tulana	Opill
Ingredient	Norethindrone 0.35 mg	Norethindrone 0.35 mg
Access	Prescription	Nonprescription
Differentiation	Brand, prescriber access, pharmacy channel	OTC availability and consumer convenience
Excipient opportunity	Reformulation and packaging	Consumer-oriented formulation and packaging
Patent value	Likely narrow and product-specific	Primarily commercial and regulatory execution
Main risk	Generic substitution and OTC migration	Retail competition and consumer adherence

Tulana’s strongest defense is channel differentiation. A prescription product can integrate with clinicians, insurance reimbursement, specialty pharmacies and contraceptive counseling. An OTC product can reduce access friction and serve consumers who do not seek a prescription. Excipient changes alone are unlikely to offset this access difference.

What commercial opportunities exist for Tulana excipients?

Prescription adherence packaging

Calendar blister packs, dose-reminder labels and mail-order-compatible packaging could improve daily use. The value can be measured through refill persistence, missed-dose reports and pharmacy claims.

Global formulation harmonization

A lactose-free or broadly accepted excipient platform could simplify regional registrations. Harmonization can reduce manufacturing complexity, but excipients remain subject to local regulatory acceptability and pharmacopoeial requirements.

Private-label and contract manufacturing

A reliable low-dose tablet platform could support private-label contraceptive products, payer-specific packaging and international licensing. The commercial asset would be the manufacturing process and supply chain rather than the norethindrone molecule.

Consumer-centered delivery formats

Orally disintegrating tablets, mini-tablets and improved-mouthfeel products could create premium positioning. These formats require evidence that the patient benefit is material and that dissolution and bioequivalence remain acceptable.

Supply-chain resilience

Dual-source excipients, validated alternate suppliers and robust moisture-control packaging could reduce shortages. For a daily contraceptive, consistent availability has direct commercial value and may support preferred formulary or pharmacy placement.

How strong is the patent estate for Tulana?

Tulana’s likely patent estate is weaker than estates surrounding new chemical entities, long-acting injectables or complex drug-device products. The practical protection hierarchy is:

1. Regulatory and brand positioning.
2. Manufacturing know-how.
3. Packaging and adherence systems.
4. Narrow formulation patents.
5. Broad active-ingredient patents, which are not commercially realistic for established norethindrone.

A successful life-cycle strategy should prioritize measurable patient or manufacturing advantages. A conventional excipient substitution without clinical, stability or process evidence is unlikely to create durable exclusivity.

Key Takeaways

• Tulana is a 0.35 mg norethindrone progestin-only tablet.
• Its main risks are generic substitution, OTC migration to Opill and limited active-ingredient exclusivity.
• The best excipient opportunities are lactose-free formulation, improved swallowability, orally disintegrating formats, content-uniformity controls and moisture-protective packaging.
• Formulation patents must be tied to measurable technical performance, not routine excipient substitution.
• The Orange Book and current FDA labeling control any conclusion about listed patents, exclusivity and inactive ingredients.
• Commercial value is more likely to come from access, packaging, supply reliability and manufacturing economics than from a broad patent position.

FAQs

Can Tulana be reformulated without a new FDA approval?

A material change to excipients, dosage form, manufacturing process or release characteristics generally requires an FDA submission and supporting CMC, stability and bioequivalence information. The required pathway depends on the approved product’s regulatory status and the scope of the change.

Would a lactose-free Tulana have meaningful market exclusivity?

Lactose-free status alone is unlikely to provide strong exclusivity. It may support a formulation patent only if the product demonstrates a non-obvious technical advantage and satisfies patentability requirements.

Is an excipient patent enough to block generic norethindrone?

Usually not. A generic applicant may design around a narrow excipient claim or use a different formulation. Blocking power depends on claim scope, Orange Book listing, infringement exposure and the availability of alternative formulations.

Could Tulana be converted to an OTC product?

Potentially, but OTC conversion would require FDA review of consumer labeling, safe-use conditions, self-selection, actual-use behavior and nonprescription suitability. Opill’s approval establishes a regulatory precedent for OTC norethindrone but does not automatically convert Tulana.

Are biosimilars a competitive threat to Tulana?

No. Tulana contains a synthetic small-molecule hormone, not a biologic. Competition proceeds through generic and alternative contraceptive pathways rather than biosimilar approval.

References

1. DailyMed. (n.d.). Tulana: Norethindrone tablet, 0.35 mg, prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2023, July 13). FDA approves first nonprescription daily oral contraceptive.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format of an abbreviated new drug application.